Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer

NCT00288002 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT00288002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00288002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
Not reported
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer